GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Bachem Holding AG (OTCPK:BCHMY) » Definitions » COGS-to-Revenue

BCHMY (Bachem Holding AG) COGS-to-Revenue : 0.67 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Bachem Holding AG COGS-to-Revenue?

Bachem Holding AG's Cost of Goods Sold for the six months ended in Dec. 2024 was $272.9 Mil. Its Revenue for the six months ended in Dec. 2024 was $409.3 Mil.

Bachem Holding AG's COGS to Revenue for the six months ended in Dec. 2024 was 0.67.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Bachem Holding AG's Gross Margin % for the six months ended in Dec. 2024 was 33.33%.


Bachem Holding AG COGS-to-Revenue Historical Data

The historical data trend for Bachem Holding AG's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bachem Holding AG COGS-to-Revenue Chart

Bachem Holding AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.67 0.68 0.69 0.70

Bachem Holding AG Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.76 0.65 0.75 0.67

Bachem Holding AG COGS-to-Revenue Calculation

Bachem Holding AG's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=474.096 / 678.846
=0.70

Bachem Holding AG's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=272.899 / 409.317
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bachem Holding AG  (OTCPK:BCHMY) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Bachem Holding AG's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 272.899 / 409.317
=33.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Bachem Holding AG COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bachem Holding AG's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Bachem Holding AG Business Description

Address
Hauptstrasse 144, Bubendorf, CHE, 4416
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. It has two geographic segments Europe/Asia and USA. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities.